NTI · ASX

Neurotech International Ltd. (ASX:NTI)

AU$0.018

 -0.001 (-5.263%)
ASX:Live
11/07/2025 04:10:22 PM
HALO Ords GROWTH AUS Big Candle All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

NTI Overview

NTI Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About NTI

Website

Neurotech International Ltd.

Telephone

61.8.9389.3130

Address

Suite 102 Level 1 55 Collins Street Melbourne, Victoria (VIC) 3000

Description

Neurotech International Ltd. engages in the research, design, development, and manufacture of medical devices and solutions in Australia. Its product includes Mente Autism for the diagnosis and treatment of autism. The company was founded on January 15, 2016 and is headquartered in Nedlands, Australia.

NTI Price Chart

Key Stats

Market Cap

AU$19.94M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.01 - 0.09

Trade Value (12mth)

AU$9,523.00

1 week

0%

1 month

0%

YTD

-66.07%

1 year

-77.38%

All time high

0.49

Key Fundamentals

EPS 3 yr Growth

-62.90%

EBITDA Margin

%

Operating Cashflow

-$5m

Free Cash Flow Return

-57.90%

ROIC

-63.90%

Interest Coverage

N/A

Quick Ratio

38.80

Other Data

Shares on Issue (Fully Dilluted)

1023m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

NTI Announcements

Latest Announcements

Date Announcements

10 July 25

Change of Registered Address & Principal Place of Business

×

Change of Registered Address & Principal Place of Business

09 July 25

Becoming a substantial holder

×

Becoming a substantial holder

07 July 25

New Scientific Publication of Phase I/II Rett Syndrome Trial

×

New Scientific Publication of Phase I/II Rett Syndrome Trial

16 June 25

NTI Appoints Dr. Bonni Goldstein as Chief Medical Advisor

×

NTI Appoints Dr. Bonni Goldstein as Chief Medical Advisor

06 June 25

NTI164 to be presented at IRSF Annual Scientific Meeting

×

NTI164 to be presented at IRSF Annual Scientific Meeting

02 June 25

Positive Human PK Study Results for NTI164

×

Positive Human PK Study Results for NTI164

05 May 25

NTI164 Preclinical Toxicology Studies Update

×

NTI164 Preclinical Toxicology Studies Update

28 April 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

16 April 25

Updated Trading Policy

×

Updated Trading Policy

02 April 25

Final Director's Interest Notice

×

Final Director's Interest Notice

02 April 25

Application for quotation of securities - NTI

×

Application for quotation of securities - NTI

02 April 25

Secondary Trading Notice

×

Secondary Trading Notice

01 April 25

Resignation of Executive Director

×

Resignation of Executive Director

31 March 25

European Commission grants NTI164 ODD for Rett Syndrome

×

European Commission grants NTI164 ODD for Rett Syndrome

26 March 25

Retraction of Statement

×

Retraction of Statement

24 March 25

New Scientific Publication of Phase I/II Autism Trial

×

New Scientific Publication of Phase I/II Autism Trial

20 March 25

Neurotech Presentation at NWR Virtual Healthcare Conference

×

Neurotech Presentation at NWR Virtual Healthcare Conference

18 March 25

Neurotech to present at NWR Virtual Healthcare Conference

×

Neurotech to present at NWR Virtual Healthcare Conference

27 February 25

Positive Opinion on OMPD for NTI164 in Europe

×

Positive Opinion on OMPD for NTI164 in Europe

27 February 25

Appendix 4D and Half Year Accounts

×

Appendix 4D and Half Year Accounts

24 February 25

Notification regarding unquoted securities - NTI

×

Notification regarding unquoted securities - NTI

24 February 25

Change of Director's Interest Notice

×

Change of Director's Interest Notice

13 February 25

NTI Signs Development Agreement for Cannabinoid Therapies

×

NTI Signs Development Agreement for Cannabinoid Therapies

04 February 25

Initial Director's Interest Notice

×

Initial Director's Interest Notice

31 January 25

Neurotech Receives $2.44 Million R&D Tax Incentive Refund

×

Neurotech Receives $2.44 Million R&D Tax Incentive Refund

NTI Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.00 -0.01 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.00 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 68.2 -104.2 42.9 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.01 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.00 -0.01 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -22.6 -68.4 64.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock -6.1 -19.8 0.0 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.00 0.00 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.00 0.00 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -63.0 121.2 158.0 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 697 799 912 Lock Lock Lock
Basic m Lock Lock Lock Lock 697 799 912 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -81.4 -84.4 -67.1 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 3 9 9 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -1 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -124.2 100.8 -100.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,398.8 70.7 0.0 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 1,499 29 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -4 -9 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock 47.4 -130.0 2.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -10,243.8 -151,313.1 -446,264.4 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -4 -9 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock 47.3 -130.1 2.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -10,245.3 -151,342.3 -446,293.9 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -4 -9 -8 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -1 -3 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -3 -8 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock 54.8 -131.7 34.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -8,787.4 -130,759.2 -258,240.0 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -3 -6 -5 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 9 11 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -3 -6 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -27.7 -113.5 100.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -77.3 -1,060.1 0.0 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 2 5 12 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 2 5 12 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -2 -5 -12 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 1 0 Lock Lock Lock
Equity $m Lock Lock Lock Lock 1 4 12 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 1 4 12 Lock Lock Lock
     Growth % Lock Lock Lock Lock -63.0 177.1 200.3 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -166.2 -146.8 -41.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -235.1 -196.7 -42.6 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -148.2 -334.5 -110.5 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -127.1 -289.0 -63.9 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -111.7 -234.3 -57.9 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -2,863.0 N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.5 0.6 1.3 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -132.5 -126.9 -97.7 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 3.4 3.9 38.8 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 3.4 3.9 38.8 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 93.8 94.7 95.2 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -498.4 -469.0 -1,460.2 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.3 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 159.3 0.2 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 1,359.2 21,632.8 14,201.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -10,275.4 -150,704.3 -420,001.1 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -194.3 -169.2 -67.5 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -166.2 -146.8 -41.5 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.4 1.3 1.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -235.1 -196.7 -42.6 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -235.1 -196.7 -42.6 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 2.3 1,567.9 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 1,155.9 10,934.8 53,514.9 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 1,158.2 12,502.7 53,514.9 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 265.3 140,384.6 0.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 892.9 -127,881.9 53,514.9 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

NTI Shortsell

Frequently Asked Questions

The current share price of Neurotech International Ltd. (NTI:ASX) is AU$0.018.
The 52-week high share price for Neurotech International Ltd. (NTI:ASX) is AU$0.09.
The 52-week low share price for Neurotech International Ltd. (NTI:ASX)? is AU$0.01.
Neurotech International Ltd. (NTI:ASX) does not pay a dividend.
Neurotech International Ltd. (NTI:ASX) does not pay a dividend.
Neurotech International Ltd. (NTI:ASX) has a franking level of 0.0%.
Neurotech International Ltd. (NTI:ASX) is classified in the Healthcare.
The current P/E ratio for Neurotech International Ltd. (NTI:ASX) is .
The current share price of Neurotech International Ltd. (NTI:ASX) is AU$0.018.
The 52-week high share price for Neurotech International Ltd. (NTI:ASX) is AU$0.09.
The 52-week low share price for Neurotech International Ltd. (NTI:ASX)? is AU$0.01.
Neurotech International Ltd. (NTI:ASX) does not pay a dividend.
Neurotech International Ltd. (NTI:ASX) does not pay a dividend.
Neurotech International Ltd. (NTI:ASX) has a franking level of 0.0%.
Neurotech International Ltd. (NTI:ASX) is classified in the Healthcare.
The current P/E ratio for Neurotech International Ltd. (NTI:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.